Eli Lilly (LLY) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $8.38
- EPS estimate
- $6.01
- EPS surprise
- +39.52%
- Revenue surprise
- +11.07%
- Revenue
- $23.0B
- Revenue estimate
- $20.7B
- Reported
- Aug 5, 2026
Eli Lilly's Q2 2026 results, reported August 5, 2026, brought the highest quarterly revenue in the table. Revenue was $23.0 billion against a $20.7 billion estimate, an 11.07% beat. Earnings per share were $8.38, beating the $6.01 estimate by 39.52%. Compared with Q2 2025, EPS rose 32.8% from $6.31 and revenue rose 47.4% from $15.6 billion. EPS was 2.0% below Q1 2026's $8.55, the peak in the table.
The longer record shows fast but uneven growth. Annual EPS went from $7.94 in 2022 to $6.32 in 2023, then $13.00 in 2024 and $24.21 in 2025. Annual revenue rose from $28.5 billion to $65.2 billion over the same years. Quarterly EPS has swung widely, from a low of $0.10 in Q3 2023. Across the last 20 quarters, Eli Lilly beat EPS estimates 16 times. The largest miss was 26.48%, in Q2 2022, and the most recent was in Q3 2024.
Eli Lilly has reported its third quarter between October 26 and November 2 in recent years, so the next report is likely in late October or early November 2026. First-half 2026 EPS totals $16.93, 75.4% above a year earlier. The key question is whether revenue keeps rising from $23.0 billion.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $6.01 | $8.38 | +39.52% | $23.0B | SEC |
| Q1 2026 | Apr 30, 2026 | $6.97 | $8.55 | +22.71% | $19.8B | SEC |
| Q4 2025 | Feb 4, 2026 | $6.91 | $7.54 | +9.10% | $19.3B | SEC |
| Q3 2025 | Oct 30, 2025 | $5.69 | $7.02 | +23.33% | $17.6B | SEC |
| Q2 2025 | Aug 7, 2025 | $5.60 | $6.31 | +12.70% | $15.6B | SEC |
| Q1 2025 | May 1, 2025 | $3.26 | $3.34 | +2.51% | $12.7B | SEC |
| Q4 2024 | Feb 6, 2025 | $5.04 | $5.32 | +5.45% | $13.5B | SEC |
| Q3 2024 | Oct 30, 2024 | $1.42 | $1.18 | −16.97% | $11.4B | SEC |
| Q2 2024 | Aug 8, 2024 | $2.74 | $3.92 | +42.93% | $11.3B | SEC |
| Q1 2024 | Apr 30, 2024 | $2.47 | $2.58 | +4.64% | $8.8B | SEC |
| Q4 2023 | Feb 6, 2024 | $2.30 | $2.49 | +8.45% | $9.4B | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.18 | $0.10 | +155.90% | $9.5B | SEC |
| Q2 2023 | Aug 8, 2023 | $1.98 | $2.11 | +6.61% | $8.3B | SEC |
| Q1 2023 | Apr 27, 2023 | $1.73 | $1.62 | −6.13% | $7.0B | SEC |
| Q4 2022 | Feb 2, 2023 | $1.78 | $2.09 | +17.22% | $7.3B | SEC |
| Q3 2022 | Nov 1, 2022 | $1.91 | $1.98 | +3.44% | $6.9B | SEC |
| Q2 2022 | Aug 4, 2022 | $1.70 | $1.25 | −26.48% | $6.5B | SEC |
| Q1 2022 | Apr 28, 2022 | $2.29 | $2.62 | +14.30% | $7.8B | SEC |
| Q4 2021 | Feb 3, 2022 | $2.45 | $2.49 | +1.79% | $8.0B | SEC |
| Q3 2021 | Oct 26, 2021 | $1.96 | $1.94 | −1.16% | $6.8B | SEC |
Quarterly revenue
Frequently asked questions
When did Eli Lilly (LLY) last report earnings?
Eli Lilly last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did LLY beat earnings estimates?
Yes. Eli Lilly reported EPS of $8.38 for Q2 2026 against a $6.01 estimate — a 39.52% beat.
How much revenue did LLY report last quarter?
Eli Lilly reported $23.0B in revenue for Q2 2026, against a consensus estimate of $20.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.